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Highlights 
 Here we present a series of eight patients from seven families presenting with exercise 
intolerance, myalgia and rhabdomyolysis caused by mutations in CAV3 
 This case series broadens the phenotypic spectrum of caveolinopathies. 
 Exercise intolerance, myalgia and rhabdomyolysis may be caused by CAV3 
mutations. 
 Rippling muscle contractions and percussion-induced rapid muscle contractions 
(PIRCs) are important clinical clues indicative of caveolinopathies. 
 Immunoblotting may be a more sensitive method to detect reduced caveolin-3 levels 
than immunohistochemistry. 
 
Abstract: 
Rhabdomyolysis is often due to a combination of environmental trigger(s) and genetic 
predisposition; however, the underlying genetic cause remains elusive in many cases. 
Mutations in CAV3 lead to various neuromuscular phenotypes with partial overlap, including 
limb girdle muscular dystrophy type 1C (LGMD1C), rippling muscle disease, distal 
myopathy and isolated hyperCKemia. Here we present a series of eight patients from seven 
families presenting with exercise intolerance and rhabdomyolysis caused by mutations in 
CAV3 diagnosed by next generation sequencing (NGS) (n=6). Symptoms included myalgia 
(n=7), exercise intolerance (n=6) and episodes of rhabdomyolysis (n=2). Percussion-induced 
rapid muscle contractions (PIRCs) were seen in five out of six patients examined. A 
previously reported heterozygous mutation in CAV3 (p.T78M) and three novel variants 
(p.V14I, p.F41S, p.F54V) were identified.  Caveolin-3 immunolabeling in muscle was 
normal in 3/4 patients however, immunoblotting showed more than 50% reduction of 
caveolin-3 in five patients compared with controls. This case series demonstrates that 
Comment [A1]: Author: There are two different 
highlights were provided and the one in the 
manuscript has been retained. Please check and 
confirm it is correct. 
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exercise intolerance, myalgia and rhabdomyolysis may be caused by CAV3 mutations and 
broadens the phenotypic spectrum of caveolinopathies. In our series immunoblotting was a 
more sensitive method to detect reduced caveolin-3 levels than immunohistochemistry in 
skeletal muscle. Patients presenting with muscle pain, exercise intolerance and 
rhabdomyolysis should be routinely tested for PIRCs as this may be an important clinical clue 
for caveolinopathies, even in the absence of other “typical” features. The use of NGS may 
expand current knowledge concerning inherited diseases, and unexpected/atypical 
phenotypes may be attributed to well-known human disease genes. 
 
Key Words: CAV3; Rhabdomyolysis; Myoglobinuria; Caveolinopathy; Exercise Intolerance; 
Myalgia 
Abbreviations: 
ATPase: Adenosine triphosphatase 
CAV3: Caveolin-3 (M-caveolin) – OMIM # 601253 
CK: creatine kinase 
COX: cytochrome oxidase 
CPT2: Carnitine Palmitoyl Transferase 2 
CRP: C-reactive protein 
ECC: Excitation-contraction coupling  
EM: Electron microscope 
ESR: Erythrocyte sedimentation rate 
H&E: Hematoxylin and eosin 
LGMD1C: limb girdle muscular dystrophy type 1C 
MHC: Myosin heavy chain 
MRI: Magnetic resonance imaging  
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NADH-TR: Nicotinamide adenine dinucleotide-tetrazolium reductase 
NGS: Next-generation sequencing  
nNOS: Neuronal nitric oxidase synthase 
PIRCs: percussion-induced rapid muscle contractions 
PFK: phosphofructokinase 
RM: Acute Rhabdomyolysis 
SDH: Succinic dehydrogenase 
SR: Sarcoplasmic reticulum 
WB: Western blotting 
WES: Whole exome sequencing 
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1 Introduction 
 
Acute rhabdomyolysis (RM) is a serious event often requiring critical care management. 
Precipitating causes include a range of environmental trigger(s) with and without a known 
genetic predisposition [1]. In many cases no cause is found. Here we report eight patients 
who on next-generation sequencing (NGS) were found to carry four heterozygous missense 
CAV3 mutations after extensive earlier investigations had been negative. Our findings expand 
the CAV3-related phenotypical spectrum, so far comprising limb girdle muscular dystrophy 
type 1C  (LGMD1C), rippling muscle disease, distal myopathy, isolated hyperCKemia and 
familial hypertrophic cardiomyopathy [2]. 
2 Materials and methods: 
Eight patients presenting with exercise intolerance, myalgia and/or recurrent RM who 
remained genetically unresolved despite extensive previous investigations are reported. Six 
patients (patients 1-5 and 8) were identified from a larger cohort of 225 patients with exercise 
intolerance, myalgia and/or recurrent RM. DNA from patient 6 (the father of patient 5) was 
assessed following a genetic diagnosis in his son. Patient 7 was genetically investigated 
following muscle biopsy analysis. Approval was obtained from the regional ethics 
committee, and informed consent was obtained from all subjects for genetic studies. Medical 
notes were reviewed retrospectively and patients were reassessed following the genetic 
diagnosis, except patients 1,3 and 4 who failed to attend follow up visits, and patient 6, who 
is deceased. Clinical findings are summarized in Table 1, including: age of onset, age at 
assessment, presenting symptom, recurrent RM and its triggers, reported rippling muscle 
contraction, percussion-induced rapid muscle contractions (PIRCs) assessed during physical 
exam (by a reflex hammer (percussion of a muscle)), muscle pain, muscle weakness assessed 
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during physical exam, reported exercise intolerance (defined as pain and/or a cramp-like 
sensation during exercise), fatigue and baseline serum creatine kinase (CK) levels. 
Histopathological studies were performed as described in Supplementary Material. 
Polyacrylamide gel electrophoresis and western blotting were performed as previously 
described [3]. Blots were incubated with 43DAG/8D5 (β-dystroglycan, Leica Biosystems, 
NCL-b-DG, dil. 1/350) and caveolin-3 (BD Biosciences BD610421, dil. 1/350).  Myosin 
heavy chain staining with Coomassie blue on the post-blotted gel was used as a control for 
protein loading and quality of the transfer.  Bands were visualised with SuperSignal West 
Pico Chemiluminescent Substrate detection (Life Technology) using AlphaInnotech 
FluorChemR Q platform and AlphaViewR software v3.0.  Densitometric analysis was 
undertaken using ImageJ v1.47 software with data normalised to the density of the myosin 
heavy chain band on the Coomassie blue stained post-blotted gel and expressed as a 
percentage of the control sample. 
DNA from six patients was sequenced by a NGS Illumina ‘Trusight One’ enrichment 
panel; designed to screen for 50 relevant genes, previously associated or putatively linked 
with RM (for review [1]). Mutations identified on NGS were confirmed by Sanger 
sequencing. Patient 7 was evaluated by bi-directional sequence analysis for mutations in 
CAV3 and patient 8 by whole exome sequencing (SOLiD
TM
). Whole exome sequencing was 
performed as outlined previously [4]. Three μg of DNA was fragmented by sonication and 
ligated to SOLiD
TM
 system sequencing adaptors. The resulting library was enriched for 
exomic sequences using the SeqCap EZ Human Exome Library v2.0 exome capture system 
(Nimblegen, Roche Diagnostics) and sequenced using a 5500XL Genetic Analyser (Life 
Technologies). After sequencing and alignment, average coverage was 56-fold with 73% of 
the exome covered to 20-fold or greater. Variant calling was performed using LifeScopeTM 
2.5 (Life Technologies) and the resulting variants were filtered using ANNOVAR. The CAV3 
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mutations were confirmation by bi-directional Sanger sequencing. Mutations were described 
using the single letter nomenclature to describe non-synonymous variants.  
3 Results: 
The clinical history from each patient is outlined below and key findings are summarized 
in Table 1. Patient 1 presented with fatigue, muscle pain, and recurrent episodes of 
myoglobinuria (highest CK: 28,000 IU/L) without apparent trigger. Inflammatory markers 
(CRP and ESR), HIV testing and auto-antibodies for auto-immune myositis were negative. 
Plasma acylcarnitine profile, urine organic acids, fatty acid oxidation flux and CPT2 activity 
in skin fibroblasts were all normal. Patient 2 presented with a longstanding history of muscle 
pain and tenderness exacerbated by mild physical activities and exercise that interfered with 
normal daily activities. Examination was unremarkable except for muscle pain evoked by 
muscle palpation. Routine biochemistry was normal, apart from raised CK. Inflammatory 
markers (CRP and ESR) and autoantibodies including ANA, GAD, Anti-DNA, Rheumatoid 
Factor, Anti-Hu, Anti-Yo, Anti-Ri, were negative. Patient 3 had exercise intolerance 
throughout adult life. RM occurred at age 37 following a few hours of moderate intensity 
swimming. At the time he was also taking antibiotics for an infection. Severe pain and acute 
muscle weakness were accompanied by myoglobinuria. A second episode was associated 
with exercise (swimming) in conjunction with fever. A third episode occurred spontaneously 
with no apparent precipitant. Patient 4 presented with exercise-related muscle cramps and 
stiffness since childhood. Examination was unremarkable. He had hypoglycaemic seizures in 
the neonatal period. Genetic testing for GLUT1, HADH and LPIN1 were normal. Patient 5 
had muscle symptoms from childhood. He had mild muscle weakness, and could not perform 
endurance activities. Paroxysmal weakness lasting 2-3 hours occurred after strenuous 
exercise. Post exercise muscle pain was also a feature. Hypertrophic cardiomyopathy was 
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diagnosed in his 40s during a routine health check. Extensive genetic investigations were 
negative (including full mutation screening of VCP, DES, MYOT, CRYAB, ZASP, TTN, 
targeted sequencing of POLG1 and PEO1, plus testing for large scale rearrangements and full 
sequencing of muscle-extracted mtDNA). Muscle biopsy slides were not available for review. 
Patient 6, the father of patient 5, presented with progressive muscle weakness from the fourth 
decade and died aged 85. Muscle weakness initially involved the anterior thighs with 
progression to the distal upper limbs later in life. He became wheelchair-dependent in his late 
60s. He had no swallowing or respiratory difficulties and no facial or axial weakness, no 
ptosis and a full range of eye movements. A muscle biopsy performed at 67 years was 
reported as showing dystrophic features (muscle biopsy slides not available for review). 
Genetic investigations for FKRP, VCP and dystrophin gene mutations and FSHD testing 
were all negative. Patient 7 presented with exercise intolerance and muscle pain relieved by 
rest. He occasionally experienced muscle cramps post exertion with muscle rippling.  He had 
mild proximal weakness (MRC 4+/5) with a modified Gowers’ manoeuvre. He walked with a 
mild wide-based gait with everted flat feet and had mild tightness of the tendon achilles (-5 
degrees bilaterally) and a mild lumbar lordosis. Serum lactate, acylcarnitine profile and 
routine biochemistry were normal. Patient 8 was an elite athlete, but her high level training 
was complicated by severe exercise-induced myalgia. On examination she had muscle 
hypertrophy especially marked in the lower limbs without muscle weakness.  
Four heterozygous CAV3 mutations were found: a previously described p.T78M 
substitution (exon 2, c.233C>T) (Patients 3-6) located in the central hydrophobic trans-
membrane domain of the protein, and three novel substitutions: p.V14I (exon 1, c.40G>A) 
(Patients 1 and 2) located in the N-terminal domain of the protein, p.F41S (exon 2, 
c.122C>T) (Patient 7) and p.F54V (exon 2, c.160T>G) (Patient 8), both within the 
oligomerization domain. 
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Muscle biopsies (n=5) showed non-specific changes as seen in Fig 1 (Supplementary 
Table 1). To investigate the effect of the mutation, caveolin-3 protein expression was 
assessed by WB in five patients (Patients 1,2,4,7,8). Levels in four patients (Patients 1,2,4,8) 
were reduced by more than 50% compared to controls (Fig 2). β-dystroglycan, used as a 
loading control, also had reduced levels in three of the samples (Patients 1,2,4). Caveolin-3 
was markedly reduced on muscle tissue sections from Patient 7 and absent on WB on the 
same tissue (Supplementary Fig 1). 
4 Discussion 
We present eight patients with myalgia (n=7), exercise intolerance (n=6) and recurrent 
RM (n=2) who were found to carry mutations in CAV3; a few of them had been screened for 
selected metabolic myopathies before NGS was performed. The use of NGS is rapidly 
expanding the phenotypic spectrum of many neuromuscular disease genes, as sequencing of 
disease genes is done in an unbiased approach, influencing future classification of disease 
phenotypes and inherited disorders. This case series illustrates that a “metabolic phenotype”, 
so far more frequently recognized in association with disorders of muscle metabolism (e.g.: 
glycogen storage disorders and disorders of fatty acid metabolism), may also be part of the 
phenotypic spectrum of proteins without immediately apparent primary metabolic link such 
as caveolin-3. As opposed to disorders of muscle metabolism, there was no clear provoking 
trigger for RM episodes in the reported cases. Patient 1 had no clear trigger for several 
episodes of RM. It is unclear if exercise, infection or the combination of both contributed to 
the RM episodes in patient 3, who also developed a third episode with no apparent trigger. 
CAV3 encodes caveolin-3, a muscle specific plasma membrane protein involved in 
several processes related to the formation of caveolae, invaginations of the plasma 
membrane. Autosomal dominant – and, less frequently, recessive – CAV3 mutations have 
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been implicated in hyperCKaemia, rippling muscle disease and LGMD1C [2]. Recurrent RM 
has been previously described in only one patient with a CAV3 mutation, in whom NGS had 
not been performed to exclude other genetic causes of RM [5]. Our findings suggest that 
CAV3 mutations are a more frequent cause of myalgia, exertion intolerance and RM than 
previously thought, and ought to be considered in patients presenting with such features. The 
pathogenicity of the CAV3 variants identified and emerging genotype-phenotype correlations 
are supported on several levels: 1) Exclusion of other genetic conditions predisposing to 
similar symptoms by NGS; 2) the apparent association of CAV3-related symptoms with the 
recurrent p.V14I and p.T78M substitutions; 3) and reduced caveolin-3 protein levels on WB.  
Although myalgia, exercise intolerance and/or recurrent RM were the most prominent 
features leading to referral for further assessment, other features – hyperCKaemia, reported 
muscle rippling, PIRCs, muscle weakness and hypertrophic cardiomyopathy – were either 
noted at presentation or evolved over time, emphasizing the previously observed wide and 
overlapping phenotypical spectrum associated with CAV3 mutations. Along similar lines, 
there was also marked intrafamilial variability, with one affected son (Patient 5) having a 
different clinical picture to his father (Patient 6). PIRCs, a clinical hallmark of 
caveolinopathies, were seen in five out of six patients examined, but were only assessed after 
the genetic diagnosis had been established in 2 patients (patient 1 and 2). Four out of six 
patients reported rippling muscle contraction. We believe PIRCs and rippling muscle 
contraction are important clinical clues for caveolinopathies and should be assessed for in 
patients presenting with exercise intolerance, myalgia and RM, even if other features 
suggestive of a caveolinopathy are absent. Additional features in our series, which may or 
may not be related, included a history of neonatal hypoglycaemic seizures, previously 
reported in one patient with CAV3 mutations [5], and paroxysmal muscle weakness, a novel 
association. 
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Primary protein defects and absence of caveolin-3 staining on immunohistochemistry is 
well documented in patients with caveolinopathies [2]. The key histopathological finding in 
patient 7 was marked reduction of immunostaining for caveolin-3; in combination with an 
absent band on WB, supporting the pathogenicity of the novel p.F41S substitution. Almost 
complete absence of caveolin-3 on immunoblotting of patient 8 (p.F54V) supported 
pathogenicity. These variants were absent from or expressed at a low frequency (0.0008%) in 
ExAC, respectively. The three muscle biopsies from patients harbouring the p.V14I and 
p.T78M substitutions showed only minor non-specific histochemical findings and normal 
caveolin-3 immunostaining. However, reduced caveolin-3 levels on WB, supported the 
pathogenicity of these mutations and suggested that WB may be the more sensitive method to 
detect caveolin-3 deficiency. Reijneveld et al. also identified normal caveolin-3 
immunostaining in two patients with hyperCKaemia, one with the p.T78M substitution [6]. 
Although these and our own observations indicate sufficient caveolin-3 expression to 
generate a normal immunostaining pattern, it is currently uncertain if the p.V14I and p.T78M 
substitutions exert their pathogenic effect through relative reduction or abnormal protein 
function, or both. 
Bioinformatics analysis (Table 2) predicts that p.T78M is damaging and it has been 
described in association with long QT syndrome and sudden death [7, 8], isolated 
hyperCKaemia [6], and rippling muscle disease with proximal myopathy in a patient carrying 
a D4Z4 FSHD-sized allele [9]. Bioinformatic programs also predicted the p.F41S and p.F54V 
substitutions to be pathogenic, while the p.V14I substitution was predicted to be benign by all 
programs. 
The interaction between caveolin-3 and the skeletal muscle ryanodine receptor (RyR1), 
involved in excitation-contraction coupling (ECC) and also implicated in virally- and 
exercise induced myalgia and rhabdomyolysis [10-12], could be of potential relevance to the 
Page 12 of 19
13 
 
phenotype observed in our patients.  Both caveolin-3 and RyR1 co-localize at the T-tubule 
and sarcoplasmic reticulum (SR), and a critical role for caveolin-3 has been suggested in the 
correct localization of RyR1 to the SR and as a modifier of ECC [13, 14]. 
The significance of β-dystroglycan reduction in three WB samples is uncertain, even 
though β-dystroglycan, is a known interactor of caveolins [15, 16]. Myosin heavy chain was 
also used as a protein loading control, ensuring that this observation is not due to uneven 
loading of skeletal muscle protein. 
A limitation of this study was the inability to perform co-segregation studies in other 
family members to strengthen the pathogenicity of the CAV3 variants and to evaluate their 
penetrance. In addition, future more detailed functional characterization may clarify the 
precise pathogenic effect of the new CAV3 variants and their role in genetic counselling, and 
additional genetic modifiers with potential synergistic effects may be identified. 
5 Conclusions 
In summary, myalgia, exertion intolerance and recurrent RM are features associated with 
CAV3 mutations, highlighting the broad and expanding spectrum of caveolinopathies. 
Rippling muscle contraction and PIRCs may be important clinical clues indicative of 
caveolinopathies and should be assessed in patients who present with exertion related 
symptoms. Non-specific changes in muscle biopsy do not exclude CAV3 mutations, and WB 
and/or specific genetic testing should be performed if a caveolinopathy is strongly suspected 
on clinical grounds.  
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Legends: 
Figure 1: Quadriceps muscle biopsies were available from four patients; patients 1 (I) & 2 
(II) were biopsied as adults, while 4 (III) and 7 (IV) were biopsied at 14 years. The adults (Ia, 
IIa; HE) and one child (IIIa; HE) showed minimal non-specific changes including occasional 
small fibres. The second child (IVa; HE) showed mild myopathic changes with increased 
fibre size variation, few small granular basophilic fibres, mild internal nucleation and focal 
perimysial fatty infiltrate. Fibre typing was preserved in all cases with mild oxidative 
abnormalities ranging from slight unevenness of stain to presence of a few mini-cores (Ib, 
IIB, IIIB; NADH-TR). Occasional fibres expressed fetal myosin (IIId). Protein 
immunoanalysis revealed normal sarcolemmal/basal lamina expression of the DAG complex 
including caveolin-3 (Ic, IIc, IIIc) and beta-dystroglycan (Id, IId) except in patient 7 (IV), 
where a marked reduction was identifiable in sections (IVc). Caveolin-3 labeling in a non-
disease control (IVd). The bar in the bottom right represents 100 microns in length. 
Figure 2: Western blots showed reduced levels of caveolin-3 and β-dystroglycan (β-DG) in 
patients with CAV3 mutations (A,B,C). P1: patient 1; P2: patient 2; P4: patient 4; P8: patient 
8. Levels of caveolin-3 in patient 8 were calculated to be 0.12 of controls (using the longer 
exposure blot). Myosin heavy chain (MHC) was used as a protein loading control.  
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Table 1: Key findings in patients with CAV3 mutations. NA: not applicable; ND: no data; Rippling (reported): rippling muscle contraction 
reported by the patient; PIRCs: percussion-induced rapid muscle contractions; LL: lower limbs; UL: upper limbs; CK: creatine kinase; ECG; 
electrocardiogram; NCS-EMG: neurophysiology evaluation; CTS: carpal tunnel syndrome; MRI: magnetic resonance imaging; Family history: 
Family history for neuromuscular symptoms. 
 Patient 1  Patient 2  Patient 3  Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 
DNA analysis 
CAV3 
V14I V14I T78M T78M T78M T78M F41S F54V 
Heterozygous Heterozygous Heterozygous Heterozygous Heterozygous Heterozygous Heterozygous Heterozygous 
Ethnicity African Afro-
Caribbean 
Caucasian 
(Spanish) 
Caucasian 
(British) 
Caucasian 
(Greek 
Cypriot) 
Caucasian 
(Greek 
Cypriot) 
Caucasian Caucasian 
Gender M F M M M M M F 
Age of onset / 
age at 
assessment 
20s / 33 30s / 57 30s / 43 
 
9 / 16 Childhood / 
58 
30s / 85 7 / 12 Late teens / 26 
Presenting 
symptom 
Severe 
fatigue, 
myalgia 
Calf pain Myalgia 
following 
physical activity 
Myalgia, 
muscle cramps 
Myalgia, 
Muscle 
weakness,  
difficulty to 
keeping up 
with peers 
Muscle 
weakness 
Myalgia on 
exertion, 
fatigue, 
difficulty to 
keeping up 
with peers 
Severe exercise-
induced myalgia 
Recurrent 
Rhabdomyolysi
s 
Yes No Yes No No ND No No 
Trigger 
(Rhabdomyolys
is) 
ND NA Exertion, 
Antibiotics/infe
ction, 
Unknown 
NA NA ND NA NA 
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Rippling 
(reported) 
/ PIRCs 
Yes / Yes Yes / Yes ND / ND No / Yes Yes / Yes ND / ND Yes / No No / Yes 
Myalgia Yes Yes Yes Yes Yes ND Yes Yes 
Weakness Upper limbs Proximal 
lower limbs 
No No Handgrip – 
mild 
Proximal 
(LL) 
Distal (UL) 
Handgrip 
Proximal – 
mild 
No 
Muscle atrophy ND Thigh No No No Yes No No 
Exercise 
intolerance 
Yes Yes Yes Yes Yes ND Yes Yes 
Fatigue  Yes Yes No No Yes ND Yes Yes 
Basal CK 500 300 – 600 126 600 - 4000 142 280 300-685 217 
ECG SR with 
biphasic T 
waves V4 to 
V6 
Normal ND Normal Abnormal ND Normal Normal 
Echo 
cardiogram 
Normal ND ND Normal Abnormal ND Normal Normal 
NCS-EMG Normal CTS ND Normal Normal Myopathic 
changes 
Normal Normal 
Lower limb 
muscle MRI 
Normal  Normal ND Normal ND ND Mild fatty 
infiltration 
(rectus 
femoris, 
sartorius, 
biceps 
femoris, 
gastrocnaemi
us and 
semitendinos
us muscles). 
ND 
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Family history  Negative Negative Negative Negative Affected 
father (patient 
6), mother 
(enlarged 
heart), sister 
(fatigue), son 
(exercise 
related 
myalgia) 
Affected son 
(Patient 5) 
 
Father 
(difficulty 
with 
mobility) 
Negative 
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Table 2: Frequency of the CAV3 mutations in ExAC and the in silico predictions for each 
substitution. 
Substitu
tion 
Nov
el 
Freq 
ExAC (%) 
MutationT
aster 
Polyphen-2 SIFT 
Provea
n 
MutationAss
essor  
(Fx impact) 
cDNA 
change 
Genomic coordinates 
p.V14I yes 0.0519 
Polymorph
ism 
Benign 
Tolera
ted 
Neutral Neutral c.40G>A 
3:8775602 G / A 
(rs121909281) 
p.F41S yes 
not 
present 
Disease-
causing 
Probably 
damaging 
Damag
ing  
Deleteri
ous 
Medium c.122T>C 3:8787219 T / C 
p.F54V yes 0.0008 
Disease-
causing 
Benign 
Tolera
ted 
Deleteri
ous 
Medium c.160T>G 3:8787257 T / G 
p.T78M no 0.3038 
Disease-
causing 
Probably 
damaging 
Tolera
ted 
Neutral Low c.233C>T 
3:8787330 C / T 
(rs72546668) 
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